The author highlights Cantor Fitzgerald reiterating an overweight rating and $35 price target on Tenax Therapeutics (TENX) while shares trade near $1.95 with a ~$73M market cap. The thesis is reinforced by bio investor Dr. Daniel Schneeberger's Adar1 Capital Management position totaling 6,524,151 shares and by clinical data from the Cantor Global Healthcare Conference presentation. The author cites oral levosimendan safety, treatment effect in the HELP study, a +26.3 m 6MWD effect in patients with baseline under 333 m, and a 49% NT-proBNP reduction versus placebo as supporting evidence.